Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster III
Hematology Disease Topics & Pathways:
Biological, Diseases, Therapies, immunotherapy, Lymphoid Malignancies, Myeloid Malignancies, transplantation, stem cells
Methods: Between September 1, 2009 and December 31, 2019, 550 consecutive patients had disease relapse after HCT1 of which 28 (5%) received HCT2 and 93 (17%) received DLI.
Results: The HCT1 baseline characteristics were comparable for both groups (Table1). The median time interval from HCT1 to disease relapse was 8 months (range 1-87). Patients who had disease relapse within 6 months of HCT1 had withdrawal of immune suppression (IS) medication whereas most patients with disease relapse beyond 6 months already had had IS drugs discontinued. DLI was the treatment choice for CML, CLL and plasma cell neoplasms, or for a low level of disease relapse/progression. In the HCT2 cohort, the median age was 56 (range 31-70) and 17 (61%) patients were returned to CR with chemotherapy prior to HCT2. Three patients (11%) received a myeloablative regimen and 23 (82%) received a reduced intensity regimen (RIC). The graft source was mobilized peripheral blood in 26 patients (92%) and 20 (71%) had a different donor at HCT2. Karnofsky performance status was >90% in 11 (39%) patients at HCT2. In the DLI cohort, the median age was 60 (range 22-77) and 48 (52%) were returned to CR prior to the first DLI. Patients received a median of one DLI (range 1-4). The median CD3+ T cell dose was 1.0 X107CD3+/kg (range 0.5-30). Karnofsky performance status was >90% in 56 (67%) patients at time of DLI. Both interventions were well tolerated and the 1-year non-relapse mortality (NRM) was 21% (n=6) for HCT2 and 12% (n=11) for DLI. Acute graft-versus-host disease (aGVHD), grades 2-4, occurred in 39% and 24% of the patients who received HCT2 and DLI. The 3-year cumulative incidence of extensive chronic GVHD was 25% for HCT2 and 23% for DLI.
The median follow-up for living patients was 37 months. The median event-free survival (EFS) was 18 months for HCT2 and 5 months for DLI (Fig.1A). The estimated 3-year overall survival (OS) was 60% [95% confidence interval (CI): 39-78] for HCT2 and 30% [95% CI: 21-42] for DLI (Fig.1B). The main causes of death were disease progression (n = 4) and GVHD (n = 4) for the HCT2 cohort. The same was true for the DLI cohort, although death from progressive disease was more common (n = 43 patients) compared to death from GVHD (n = 16 patients).
Within the limitations of the small number of patients only one factor in univariate analysis was associated with an improved OS for both HCT2 and DLI and this was attainment of complete donor CD3+ T cell chimerism (>95% donor type) after either intervention. The 3-year OS for patients who attained full donor chimerism was 68% and 66% for HCT2 and DLI, respectively, compared to 33% and 24% for these groups if full donor chimerism was not achieved. The KPS at the time of DLI was significantly associated with improved OS: the median OS was 2, 8 and 19 months when KPS was <70%, 70-80% and 90-100% respectively (p=0.0026). The impact of remission duration after HCT1 associated with OS for DLI but not HCT2. Relapse within 6 months after HCT1 portended a poor prognosis for the DLI group with a median OS of 6-months compared to 19-months if relapse occurred beyond 6-months of HCT1.
Conclusion: HCT2 and DLI can both offer long-term disease control for disease relapse after HCT1 albeit only a minority of patients receive these interventions. In our analysis, HCT2 and DLI were well tolerated and the risks of NRM and GVHD appear similar to HCT1. Long-term OS for HCT2 is achieved for about half of the patients when using a RIC and when the patient is returned to CR prior to the intervention. For DLI, a higher performance status and a longer remission after HCT1 were both associated with improved long-term survival. Conditions that enable attainment of full donor chimerism are important to maximize graft-versus-tumor effect for both HCT2 and DLI.
Disclosures: Muffly: Amgen: Consultancy; Servier: Research Funding; Adaptive: Research Funding. Rezvani: Pharmacyclics: Research Funding. Sidana: Janssen: Consultancy. Shiraz: Kite, a Gilead Company: Research Funding; ORCA BioSystems: Research Funding. Meyer: Orca Bio: Research Funding. Shizuru: Jasper Therapeutics, Inc: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees. Miklos: Juno-Celgene-Bristol-Myers Squibb: Consultancy, Other: Travel support, Research Funding; Pharmacyclics: Consultancy, Other: Travel support, Patents & Royalties, Research Funding; Novartis: Consultancy, Other: Travel support, Research Funding; Kite-Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding; Janssen: Consultancy, Other: Travel support; Miltenyi Biotec: Research Funding; Adaptive Biotech: Consultancy, Other: Travel support, Research Funding; Allogene Therapeutics Inc.: Research Funding. Negrin: Biosource: Current equity holder in private company; UpToDate: Honoraria; KUUR Therapeutics: Consultancy; BioEclipse Therapeutics: Current equity holder in private company; Magenta Therapeutics: Consultancy, Current equity holder in publicly-traded company; Amgen: Consultancy.
See more of: Oral and Poster Abstracts